• Lois A Daamen, Vincent P Groot, Marc G Besselink, Koop Bosscha, Olivier R Busch, Geert A Cirkel, Ronald M van Dam, Sebastiaan Festen, Bas Groot Koerkamp, Nadia Haj Mohammad, Erwin van der Harst, de HinghIgnace H J TIHJTDepartment of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Martijn P W Intven, Geert Kazemier, Maartje Los, Gert J Meijer, Vincent E de Meijer, Vincent B Nieuwenhuijs, Bobby K Pranger, Mihaela G Raicu, SchreinemakersJennifer M JJMJDepartment of Surgery, Amphia Hospital, Breda, the Netherlands., StommelMartijn W JMWJDepartment of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands., Robert C Verdonk, Helena M Verkooijen, Izaak Quintus Molenaar, Hjalmar C van Santvoort, and Dutch Pancreatic Cancer Group.
• Department of Surgery, UMC Utrecht Cancer Center, Utrecht University, Utrecht, the Netherlands.
• Ann. Surg. 2022 Apr 1; 275 (4): 769775769-775.

ObjectiveTo evaluate whether detection of recurrent pancreatic ductal adenocarcinoma (PDAC) in an early, asymptomatic stage increases the number of patients receiving additional treatment, subsequently improving survival.Summary Of Background DataInternational guidelines disagree on the value of standardized postoperative surveillance for early detection and treatment of PDAC recurrence.MethodsA nationwide, observational cohort study was performed including all patients who underwent PDAC resection (2014-2016). Prospective baseline and perioperative data were retrieved from the Dutch Pancreatic Cancer Audit. Data on follow-up, treatment, and survival were collected retrospectively. Overall survival (OS) was evaluated using multivariable Cox regression analysis, before and after propensity-score matching, stratified for patients with symptomatic and asymptomatic recurrence.ResultsEight hundred thirty-six patients with a median follow-up of 37 months (interquartile range 30-48) were analyzed. Of those, 670 patients (80%) developed PDAC recurrence after a median follow-up of 10 months (interquartile range 5-17). Additional treatment was performed in 159/511 patients (31%) with symptomatic recurrence versus 77/159 (48%) asymptomatic patients (P < 0.001). After propensity-score matching on lymph node ratio, adjuvant therapy, disease-free survival, and recurrence site, additional treatment was independently associated with improved OS for both symptomatic patients [hazard ratio 0.53 (95% confidence interval 0.42-0.67); P < 0.001] and asymptomatic patients [hazard ratio 0.45 (95% confidence interval 0.29-0.70); P < 0.001].ConclusionsAdditional treatment of PDAC recurrence was independently associated with improved OS, with asymptomatic patients having a higher probability to receive recurrence treatment. Therefore, standardized postoperative surveillance aiming to detect PDAC recurrence before the onset of symptoms has the potential to improve survival. This provides a rationale for prospective studies on standardized surveillance after PDAC resection.Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

15 keywords...

hide…